Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones. 1979

K C Murdock, and R G Child, and P F Fabio, and R B Angier, and R E Wallace, and F E Durr, and R V Citarella

The condensation of alkylenediamines with quinizarin or with 2,3-dihydro-1,4,5,8-tetrahydroxy-9,10-anthracenedione, followed by oxidation, gave 1,4-bis[aminoalkyl)amino]-9,10-anthracenediones. Some of these compounds and their 2,3-dihydro derivatives were markedly active against both leukemias and solid tumors in mice. Activity was maximal with 5,8-dihydroxylation and 1,4-bis[(2-aminoethyl)amino] substitution, in which the terminal nitrogen atoms were either unsubstituted (compound 50) or carried 2-hydroxyethyl groups (compound 40), indicating the importance of hydrophilicity. Against B-16 melanoma, 50 gave greater than 433% increase in median life span (ILS) with 7/10 80-day survivors. Against P-388 leukemia, 40 gave greater than 500% ILS with 4/5.60-day survivors; its efficacy and therapeutic index equaled or surpassed those of adriamycin, cyclophosphamide, daunorubicin, methotrexate, or 5-fluorouracil. Against L-1210 leukemia, B-16 melanoma, and colon tumor 26, 40 was generally as effective or more effective than adriamycin and is now undergoing preclinical toxicological evaluation.

UI MeSH Term Description Entries
D007942 Leukemia, Experimental Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues. Experimental Leukemia,Experimental Leukemias,Leukemia Model, Animal,Leukemias, Experimental,Animal Leukemia Model,Animal Leukemia Models,Leukemia Models, Animal
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000873 Anthracenes A group of compounds with three aromatic rings joined in linear arrangement.
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

K C Murdock, and R G Child, and P F Fabio, and R B Angier, and R E Wallace, and F E Durr, and R V Citarella
August 1991, Journal of medicinal chemistry,
K C Murdock, and R G Child, and P F Fabio, and R B Angier, and R E Wallace, and F E Durr, and R V Citarella
August 1989, Journal of medicinal chemistry,
K C Murdock, and R G Child, and P F Fabio, and R B Angier, and R E Wallace, and F E Durr, and R V Citarella
February 1995, Journal of medicinal chemistry,
K C Murdock, and R G Child, and P F Fabio, and R B Angier, and R E Wallace, and F E Durr, and R V Citarella
August 1986, Journal of medicinal chemistry,
K C Murdock, and R G Child, and P F Fabio, and R B Angier, and R E Wallace, and F E Durr, and R V Citarella
October 1988, Journal of medicinal chemistry,
K C Murdock, and R G Child, and P F Fabio, and R B Angier, and R E Wallace, and F E Durr, and R V Citarella
August 1985, Journal of medicinal chemistry,
K C Murdock, and R G Child, and P F Fabio, and R B Angier, and R E Wallace, and F E Durr, and R V Citarella
March 1994, Journal of medicinal chemistry,
K C Murdock, and R G Child, and P F Fabio, and R B Angier, and R E Wallace, and F E Durr, and R V Citarella
September 1990, Journal of medicinal chemistry,
K C Murdock, and R G Child, and P F Fabio, and R B Angier, and R E Wallace, and F E Durr, and R V Citarella
February 1981, Biochemical pharmacology,
K C Murdock, and R G Child, and P F Fabio, and R B Angier, and R E Wallace, and F E Durr, and R V Citarella
November 2006, Organic & biomolecular chemistry,
Copied contents to your clipboard!